TY - JOUR
T1 - Genome mining for ribosomally synthesized natural products
AU - Velásquez, Juan E.
AU - Van der Donk, Wilfred A.
N1 - Funding Information:
Our work on RiPPs is supported by the National Institutes of Health ( GM58822 to WAV). JEV was supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award T32 GM070421 .
PY - 2011/2
Y1 - 2011/2
N2 - In recent years, the number of known peptide natural products that are synthesized via the ribosomal pathway has rapidly grown. Taking advantage of sequence homology among genes encoding precursor peptides or biosynthetic proteins, in silico mining of genomes combined with molecular biology approaches has guided the discovery of a large number of new ribosomal natural products, including lantipeptides, cyanobactins, linear thiazole/oxazole-containing peptides, microviridins, lasso peptides, amatoxins, cyclotides, and conopeptides. In this review, we describe the strategies used for the identification of these ribosomally synthesized and posttranslationally modified peptides (RiPPs) and the structures of newly identified compounds. The increasing number of chemical entities and their remarkable structural and functional diversity may lead to novel pharmaceutical applications.
AB - In recent years, the number of known peptide natural products that are synthesized via the ribosomal pathway has rapidly grown. Taking advantage of sequence homology among genes encoding precursor peptides or biosynthetic proteins, in silico mining of genomes combined with molecular biology approaches has guided the discovery of a large number of new ribosomal natural products, including lantipeptides, cyanobactins, linear thiazole/oxazole-containing peptides, microviridins, lasso peptides, amatoxins, cyclotides, and conopeptides. In this review, we describe the strategies used for the identification of these ribosomally synthesized and posttranslationally modified peptides (RiPPs) and the structures of newly identified compounds. The increasing number of chemical entities and their remarkable structural and functional diversity may lead to novel pharmaceutical applications.
UR - http://www.scopus.com/inward/record.url?scp=79851508812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79851508812&partnerID=8YFLogxK
U2 - 10.1016/j.cbpa.2010.10.027
DO - 10.1016/j.cbpa.2010.10.027
M3 - Review article
C2 - 21095156
AN - SCOPUS:79851508812
SN - 1367-5931
VL - 15
SP - 11
EP - 21
JO - Current Opinion in Chemical Biology
JF - Current Opinion in Chemical Biology
IS - 1
ER -